Sign in to view content

Improvement of Worsening in Diabetic Retinopathy Through 2 Years in a Randomized Trial

Susan B. Bressler, MD, FASRS

Video
Published 2017

Related

Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Should We Ever Consider Stopping Treatment for Neovascular AMD?
Rahul N. Khurana, MD, FASRS
Updates from the Field
2020
Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021

Category: Diabetic Retinopathy

See more